

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天辰生物

LongBio Pharma (Suzhou) Co., Ltd.

天辰生物醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1779)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 30, 2026

References are made to the notice (the “**AGM Notice**”) of 2025 annual general meeting (the “**AGM**”) and the circular (the “**Circular**”) of LongBio Pharma (Suzhou) Co., Ltd. (the “**Company**”) both dated June 9, 2026. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the AGM Notice and the Circular.

The AGM was held at 4:00 p.m. on Tuesday, June 30, 2026 at the 5th Floor, Building F, Area A, No. 128 Yinhe Road, Dongnan Subdistrict, Changshu City, Suzhou City, Jiangsu Province, PRC. All of the Directors attended the AGM in person or by electronic means.

As at the date of the AGM, the total number of issued Shares of the Company was 74,193,150, comprising 72,930,268 H Shares and 1,262,882 Unlisted Shares, which was the total number of Shares entitling the holders to attend and vote on the resolutions proposed at the AGM. The Company did not hold any treasury Shares (including any treasury Shares held or deposited with the CCASS established and operated by HKSCC) or repurchased Shares which are pending cancellation. No Shareholders were required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favor of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules. None of the Shareholders has stated his/her/its intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM. The convening of the AGM was in compliance with the relevant requirements of the Company Law and the Articles of Association.

Shareholders and duly authorized proxies, holding a total of 44,007,989 Shares, representing approximately 59.32% of the total number of issued Shares, were present at the AGM. The resolutions at the AGM were put to vote by way of poll.

POLL RESULTS OF THE AGM

The Board is pleased to announce that the following resolutions have been duly passed at the AGM and the details of the poll results are set out as follows:

ORDINARY RESOLUTIONS		NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.	To receive, consider and adopt the accountant's report for the year ended December 31, 2025.	44,007,989 100.00%	0 0.00%	0 0.00%
2.	To consider and approve the profit distribution plan of the Company for the year ended December 31, 2025.	44,007,989 100.00%	0 0.00%	0 0.00%
3.	To consider and approve the re-appointment of Ernst & Young as the auditor of the Company for the year ending December 31, 2026 and that will hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix its remuneration.	44,007,989 100.00%	0 0.00%	0 0.00%
SPECIAL RESOLUTIONS		FOR	AGAINST	ABSTAIN
4.	To consider and approve the proposal regarding the grant of a general mandate to the Board to issue Shares.	43,356,089 98.52%	651,900 1.48%	0 0.00%
5.	To consider and approve the proposal regarding the grant of a general mandate to the Board to repurchase H Shares.	44,007,989 100.00%	0 0.00%	0 0.00%
As more than half of the votes from Shareholders (including proxies thereof) attending and having the rights to vote at the AGM were cast in favor of the resolutions numbered 1 to 3, these resolutions were duly passed as ordinary resolutions of the Company. As more than two-thirds of the votes from Shareholders (including proxies thereof) attending and having the rights to vote at the AGM were cast in favor of the resolutions numbered 4 and 5, these resolutions were duly passed as special resolutions of the Company.				

The Company's H Share Registrar in Hong Kong, Tricor Investor Services Limited, and two Shareholder representatives of the Company were appointed as the scrutineers for the purpose of vote-taking at the AGM.

By order of the Board
LongBio Pharma (Suzhou) Co., Ltd.
Dr. Liu Heng
Chairman of the Board and Executive Director

Hong Kong, June 30, 2026

As at the date of this announcement, the Board comprises (i) Dr. LIU Heng, Dr. SUN Bill Nai-chau and Mr. XIE Ming as executive Directors; (ii) Mr. LIN Jian, Ms. GU Qin, Dr. XUE Di and Dr. CHEN Kan as non-executive Directors; and (iii) Mr. SIU Paul Yu Hay, Mr. RUAN Tim, Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.